The Ministry of Health and Welfare's Centers for Disease Control and Prevention announced the results of the public tender for the quadrivalent influenza vaccine yesterday. This year, in addition to Adimmune, Sanofi, TTY Biopharm, and Medigen Vaccine, the Dutch company GlaxoSmithKline (GSK) has been included for the first time, with a total procurement of 6,882,000 doses. Adimmune secured the bid for 3.2 million doses, accounting for nearly half.
According to the CDC statistics, a total of 6,882,000 doses of the public-funded quadrivalent influenza vaccine were procured this year, including 3,150,000 doses from Adimmune, accounting for 47.5%; 1,740,000 doses from Sanofi, accounting for 26.2%; 750,000 doses from GSK, accounting for 11.3%; 600,000 doses from TTY Biopharm, accounting for 9%; and 398,200 doses from Medigen Vaccine, accounting for 6%. Additional orders of 50,000 doses per manufacturer will be placed based on actual demand.
The CDC announced the unit price per dose for each brand, with TTY Biopharm being the highest at NT$242, followed by Medigen Vaccine at NT$238, Adimmune at NT$236, GSK at NT$235, and Sanofi at NT$232. The total procurement amount for this year's public-funded quadrivalent influenza vaccine reached NT$1.622 billion.
Adimmune stated that although five manufacturers have joined the public-funded influenza vaccine this year, slightly reducing their proportion, Adimmune is the only one in Taiwan to join the International Federation of Biopharmceutical Manufacturers & Associations (IFPMA) Global Influenza Vaccine Supply Task Force (IVS), allowing participation in the World Health Organization's annual seasonal influenza virus strain selection meetings and rapid access to new influenza virus strains.
Adimmune pointed out that it initiated the production of quadrivalent influenza vaccine antigen as early as March. Adimmune's priority is to meet Taiwan's epidemic prevention needs, and production and shipment schedules are planned to ensure timely supply to meet the quantity needed for epidemic prevention. As all influenza vaccine manufacturers are participating in the public-funded influenza vaccine supply this year, Adimmune is also prepared to supply more than in previous years in the self-pay market.
Regarding the government's possible switch to procuring trivalent influenza vaccine next year, Adimmune stated that it currently holds licenses for both trivalent and quadrivalent influenza vaccines in Taiwan. Although it has not supplied trivalent influenza vaccines in Taiwan in recent years, Adimmune's trivalent influenza vaccine license is still valid. Adimmune has already begun the process of changing the production line for trivalent influenza vaccine license renewal and expects to complete it within this year.
Resource (Mandarin):
